Mainz Biomed B.V. (MYNZ): Price and Financial Metrics


Mainz Biomed B.V. (MYNZ): $11.91

0.70 (+6.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYNZ Stock Price Chart Interactive Chart >

Price chart for MYNZ

MYNZ Price/Volume Stats

Current price $11.91 52-week high $30.00
Prev. close $11.21 52-week low $7.80
Day low $11.10 Volume 19,900
Day high $12.18 Avg. volume 387,656
50-day MA $13.64 Dividend yield N/A
200-day MA $0.00 Market Cap N/A

Mainz Biomed B.V. (MYNZ) Company Bio


Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.


MYNZ Latest News Stream


Event/Time News Detail
Loading, please wait...

MYNZ Latest Social Stream


Loading social stream, please wait...

View Full MYNZ Social Stream

Latest MYNZ News From Around the Web

Below are the latest news stories about Mainz Biomed Nv that investors may wish to consider to help them evaluate MYNZ as an investment opportunity.

Mainz Biomed's pre-submission for colorectal cancer test trial accepted by FDA

Mainz Biomed (NASDAQ:MYNZ) said its pre-submission filed with the U.S. Food & Drug Administration (FDA) for ColoAlert was accepted for review. The FDA will provide feedback to the company on its proposed U.S. clinical trial design for ColoAlert, a detection test for colorectal cancer. The FDA feedback, which is expected in Q2, will provide...

Seeking Alpha | February 23, 2022

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug AdministrationBERKELEY, Calif. and MAINZ, Germany, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its pre-submission filed with the U.S. Food & Drug Administration (FDA) for ColoAlert has been accepted for review. By accepting the pre-submission for review

Yahoo | February 23, 2022

Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach

Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in EuropeLaboratory MVZ Dr. Stein + Kollegen processes over five million samples annually with a team of 500 employees that includes biologists, chemists, doctors and other specialists BERKELEY, Calif. and MAINZ, Germany, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagn

Yahoo | February 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | February 10, 2022

Mainz Biomed Appoints Oncology Expert Dr. Rainer Metzger to Strategic Advisory Board

Former DANAHER, ROCHE & QIAGEN Business Development Executive with Over 25 Years of Experience within the Pharmaceuticals and Diagnostics Industry BERKELEY, Calif. and MAINZ, Germany, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Rainer Metzger to its Strategic Advisory Board. “We’re thrilled to welcome Rainer who bri

Yahoo | February 9, 2022

Read More 'MYNZ' Stories Here

MYNZ Price Returns

1-mo -12.68%
3-mo -31.59%
6-mo 21.53%
1-year N/A
3-year N/A
5-year N/A
YTD 14.63%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3835 seconds.